Bristol Myers Squibb Non-GAAP EPS of $1.96 beats by $0.07, revenue of $11.6B beats by $260M

• Bristol Myers Squibb press release (NYSE:BMY): Q1 Non-GAAP EPS of $1.96 beats by $0.07.
• Revenue of $11.6B (+4.8% Y/Y) beats by $260M.
• Total revenue in-line with 2021  (from low single digit increase) vs. $47.1B consensus
•  EPS of $7.65-$7.95 vs. $7.74 consensus
• Revenue breakdown: Revlimid of $2.79B, Eliquis of $3.21B and Opdivo of $1.92B.